A recent retrospective study has shed new light on the effectiveness of chimeric antigen receptor T cell therapy for patients ...

Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated ...

Dr John Leonard shares key updates on DLBCL at ASH 2024, including long-term POLARIX trial data, ctDNA insights, and real-world results for polatuzumab, liso-cel, and bispecifics after CAR-T failure.

In recent years, the FDA has amped up its supervision of accelerated approvals, including by requiring that confirmatory ...

XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Diffuse Large B-Cell Lymphoma.

Panelists discuss the key challenges faced by patients with diffuse large B-cell lymphoma and follicular lymphoma at diagnosis, how these challenges evolve during treatment, and the emotional and ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within ...

As we start the New Year, it’s time to schedule your annual wellness visit. This important appointment is to talk about any ...

Brookline raised the firm’s price target on Caribou Biosciences (CRBU) to $34 from $26 and keeps a Buy rating on the shares. Caribou plans to ...

Background: Small lymphocytic lymphoma is a relatively rare B-cell non-Hodgkin lymphoma that is considered to be the tissue equivalent of the much more common entity chronic lymphocytic leukemia.